Alectinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung Cancer

  • Wu, Yi-Long; 
  • Dziadziuszko, Rafal; 
  • Ahn, Jin Seok; 
  • Barlesi, Fabrice; 
  • Nishio, Makoto; 
  • 외 17명
Citations

WEB OF SCIENCE

443
Citations

SCOPUS

490

초록

Background Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non-small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectinib as compared with chemotherapy in patients with resected ALK-positive NSCLC are lacking. Methods We conducted a global, phase 3, open-label, randomized trial in which patients with completely resected, ALK-positive NSCLC of stage IB (tumors >= 4 cm), II, or IIIA (as classified according to the seventh edition of the Cancer Staging Manual of the American Joint Committee on Cancer and Union for International Cancer Control) were randomly assigned in a 1:1 ratio to receive oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles. The primary end point was disease-free survival, tested hierarchically among patients with stage II or IIIA disease and then in the intention-to-treat population. Other end points included central nervous system (CNS) disease-free survival, overall survival, and safety. Results In total, 257 patients were randomly assigned to receive alectinib (130 patients) or chemotherapy (127 patients). The percentage of patients alive and disease-free at 2 years was 93.8% in the alectinib group and 63.0% in the chemotherapy group among patients with stage II or IIIA disease (hazard ratio for disease recurrence or death, 0.24; 95% confidence interval [CI], 0.13 to 0.45; P<0.001) and 93.6% and 63.7%, respectively, in the intention-to-treat population (hazard ratio, 0.24; 95% CI, 0.13 to 0.43; P<0.001). Alectinib was associated with a clinically meaningful benefit with respect to CNS disease-free survival as compared with chemotherapy (hazard ratio for CNS disease recurrence or death, 0.22; 95% CI, 0.08 to 0.58). Data for overall survival were immature. No unexpected safety findings were observed. Conclusions Among patients with resected ALK-positive NSCLC of stage IB, II, or IIIA, adjuvant alectinib significantly improved disease-free survival as compared with platinum-based chemotherapy. (Funded by F. Hoffmann-La Roche; ALINA ClinicalTrials.gov number, NCT03456076.)

키워드

POOLED ANALYSIS; CRIZOTINIB; MUTATIONS; SURVIVAL
제목
Alectinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung Cancer
저자
Wu, Yi-Long; Dziadziuszko, Rafal; Ahn, Jin Seok; Barlesi, Fabrice; Nishio, Makoto; Lee, Dae Ho; Lee, Jong-Seok; Zhong, Wenzhao; Horinouchi, Hidehito; Mao, Weimin; Hochmair, Maximilian; de Marinis, Filippo; Migliorino, M. Rita; Bondarenko, Igor; Lu, Shun; Wang, Qun; Ochi Lohmann, Tania; Xu, Tingting; Cardona, Andres; Ruf, Thorsten; Noe, Johannes; Solomon, Benjamin J.
DOI
10.1056/NEJMoa2310532
발행일
2024-04-11
유형
Article
저널명
New England Journal of Medicine
권
390
호
14
페이지
1265 ~ 1276